LifeVantage - LFVN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.50
  • Forecasted Upside: 82.74%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$16.69
▼ -0.09 (-0.54%)

This chart shows the closing price for LFVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
DecJanFeb$16.69Closing price on 02/21/25:
Get New LifeVantage Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LFVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LFVN

Analyst Price Target is $30.50
▲ +82.74% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for LifeVantage in the last 3 months. The average price target is $30.50, with a high forecast of $35.00 and a low forecast of $26.00. The average price target represents a 82.74% upside from the last price of $16.69.

This chart shows the closing price for LFVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
2/245/248/2411/242/253/26$3.86$12$19$27$35Closing price on 02/21/25: $16.69High$35.00Average$30.50Low$26.00




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in LifeVantage.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/14/2025Craig HallumInitiated CoverageBuy$35.00
12/19/2024Lake Street CapitalInitiated CoverageBuy$26.00
(Data available from 2/22/2020 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/27/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/26/2024
  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/25/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/25/2024
  • 3 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/24/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/24/2024
  • 7 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/23/2025
  • 5 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/22/2025

Current Sentiment

  • 5 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
LifeVantage logo
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.
Read More

Today's Range

Now: $16.69
Low: $15.98
High: $17.19

50 Day Range

MA: $20.06
Low: $15.35
High: $25.62

52 Week Range

Now: $16.69
Low: $5.22
High: $27.38

Volume

258,040 shs

Average Volume

334,250 shs

Market Capitalization

$209.46 million

P/E Ratio

29.80

Dividend Yield

0.95%

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of LifeVantage?

The following Wall Street research analysts have issued reports on LifeVantage in the last year: Craig Hallum, and Lake Street Capital.
View the latest analyst ratings for LFVN.

What is the current price target for LifeVantage?

0 Wall Street analysts have set twelve-month price targets for LifeVantage in the last year. Their average twelve-month price target is $30.50, suggesting a possible upside of 82.7%. Craig Hallum has the highest price target set, predicting LFVN will reach $35.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $26.00 for LifeVantage in the next year.
View the latest price targets for LFVN.

What is the current consensus analyst rating for LifeVantage?

LifeVantage currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LFVN will outperform the market and that investors should add to their positions of LifeVantage.
View the latest ratings for LFVN.

What other companies compete with LifeVantage?

How do I contact LifeVantage's investor relations team?

LifeVantage's physical mailing address is 9785 S. MONROE STREET SUITE 400, SANDY UT, 84070. The company's listed phone number is (801) 432-9000 and its investor relations email address is scott.vanwinkle@icrinc.com. The official website for LifeVantage is www.lifevantage.com. Learn More about contacing LifeVantage investor relations.





Receive LifeVantage News & Ratings Daily
Sign up to receive the latest news and ratings for LifeVantage and its competitors with PriceTargets.com’s free daily newsletter.